WN
HBIO icon

Williams & Novak’s Harvard Bioscience HBIO Stock Holding History

Williams & Novak’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Sell
20,949
-6,103
-23% -$36.6K 0.09% 120
2026
Q1 		$138K Sell
27,052
-7,828
-22% -$43.8K 0.1% 113
2025
Q4 		$233K Buy
34,880
+7,330
+27% +$43.5K 0.18% 98
2025
Q3 		$121K Buy
27,550
+16,893
+159% +$80.1K 0.09% 120
2025
Q2 		$47.3K Buy
10,657
+2,880
+37% +$12K 0.04% 126
2025
Q1 		$45.9K Sell
7,777
-2,144
-22% -$27.4K 0.04% 118
2024
Q4 		$209K Buy
+9,921
New +$228K 0.2% 104

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Williams & Novak's HBIO Position: Q2 2026 in Review

Williams & Novak reduced its Harvard Bioscience (HBIO) stake by 23% in Q2 2026, selling an estimated $36.6K and leaving 20,949 shares worth $129K. The position accounts for 0.09% of the portfolio, ranked #120.

Williams & Novak first reported a position in HBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $233K in Q4 2025. 37 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

  • Williams & Novak held 20,949 shares of Harvard Bioscience worth $129K as of Q2 2026.
  • Williams & Novak sold 6,103 Harvard Bioscience shares in Q2 2026, an estimated $36.6K.
  • Harvard Bioscience made up 0.09% of Williams & Novak's portfolio in Q2 2026, its #120 holding.
  • Williams & Novak first reported a position in Harvard Bioscience in Q4 2024 and has held it in 7 quarters since.
  • Williams & Novak's Harvard Bioscience position peaked at $233K in Q4 2025.
  • 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Williams & Novak's 13F filing for Q2 2026, filed 8 Jul 2026.